Alphabet and Celgene are among the investors facing a delayed exit from Rapt Therapeutics, which has postponed an initial public offering that would have raised up to $80m.

SIG-backed online lending platform developer 9f has filed for a $150m initial public offering in the US that would also enable SBI to exit.

Livongo priced its shares above their range to raise more than $355m, providing exits to Merck GHI, M12, Humana, Zaffre Investments and Echo Health Ventures.

Health Catalyst, which counts several care providers as investors, has raised $182m in its initial public offering, with its share price shooting up more than 50% on the first day of trading.

Phreesia has raised more than $167m in proceeds after pricing shares above its range at $18, providing exits to BlueCross BlueShield, Ascension Health and Echo Health Ventures.

Mirum Pharmaceuticals has raised $75m in its initial public offering that had an initial target of $86.3m and provided exits to Novo and Shire.

GlaxoSmithKline, Sanofi and 6 Dimensions Capital have all secured exits as the rare disease treatment developer raised $72m in its initial public offering.

Tencent-backed Douyu has successfully listed on Nasdaq after completing a $775m initial public offering that came after economic tensions forced a delay earlier this year.

SoftBank is the largest shareholder in CloudMinds, owning more than a third of the AI and robotics technology developer that is targeting an overseas listing in the US.

NetEase is looking to launch a $300m IPO for Youdao, which could value the Legend Holdings-backed online education services provider at $2bn.